Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Taxotere

75 mg/m2 once every 21 days for 4 cycles

DRUG

Cytoxan

600 mg/m2 once every 21 days for 4 cycles

DRUG

Trastuzumab deruxtecan

5.4 mg/kg once every 21 days for 5 cycles

DRUG

Sacituzumab govitecan

10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles

DRUG

Xeloda

1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles

DRUG

Fulvestrant

500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles

DRUG

Ribociclib

600 mg orally daily 21 days on, 7 days off

DRUG

Abemaciclib

150 mg by mouth twice daily

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER